中山大學附屬第五醫院副院長，中山大學醫學院傳染病教研室主任，附屬第五醫院感染病防治中心黨支部書記，臨床醫學、病毒學雙博士，博士后，研究員，主任醫師，博士生導師。2002年畢業于華中科技大學同濟醫學院德語醫學班（6年制），畢業后留校在附屬同濟醫院感染科從事醫教研工作，2008年獲“Charcot”獎學金，先后在法國國家健康與醫學研究院肝臟病和病毒學研究所（Inserm U1110）和美國斯坦福大學微生物和免疫系進行博士和博士后研究，2018年通過中山大學“百人計劃”引進至中山大學附屬第五醫院。在Gastroenterology（封面文章）、Gut、Journal of Hepatology、Nature Communications、PLoS Pathogens、mBio、Emerging Infectious Diseases、Journal of Virology等國際知名期刊發表SCI論文40余篇，引用超過4000次，主持2項國家自然科學基金面上項目等8項科研項目。擔任廣東省預防醫學會感染病分會常委，Frontiers in Medicine副主編。

1. 人胚胎干細胞來源的或成體細胞來源的細胞模型和類器官模型構建

2. 應用CRISPR/Cas9篩選系統等工具研究病毒和宿主相互作用的相互關系和抗病毒免疫的機制

3. 病毒性肝炎、脂肪肝、肝細胞癌的發病機制和藥物治療靶點研究

4. 新型冠狀病毒肺炎等新發突發傳染病的發病機制和治療新策略研究

在研科研項目：

1. 國家自然科學基金面上項目，82172241，應用含免疫細胞的肺類器官研究新型冠狀病毒肺炎“炎癥風暴”的機制，2022/01-2025/12,項目負責人
2. 國家自然科學基金面上項目，81870411，激酶AAK1通過磷酸化AP-2調控乙型肝炎病毒感染的機制研究，2019/01-2022/12，項目負責人

3. 廣東省自然科學基金，2019A151501038，HIF-2α激活PI3K/AKT損傷線粒體功能促進非酒精性脂肪肝相關性肝細胞癌進展的機制研究，2019/10-2022/09，項目負責人

4. 中山大學“百人計劃”-中青年杰出人才，2017/11-2022/11，項目負責人

已完成科研項目：

1. 廣東省科技計劃項目，2019A030317017，應用臍帶血干細胞構建兼具人源化免疫系統和肝臟的小鼠模型，2018/09-2021/09，項目負責人，結題
2. 珠海市“新型冠狀病毒感染防治”應急科技攻關專項，ZH22036302200028PWC，新型冠狀病毒感染引起消化道感染的機制及防治研究，2020/03-2020/12，結題

3. 中山大學高?；緲I務費青年教師重點培育項目，18ykzd03，AAK1磷酸化激活AP分子調控HBV感染的機制研究，2018/01-2019/12，結題

4. 中山大學新型冠狀病毒防控科技攻關應急專項項目，2020032308，防治新冠病毒感染引起消化道病變的臨床研究，2020/03-2020/12，結題

5. 中山大學熱帶病防治研究教育部重點實驗室開放課題，2018kfkt08， 阻斷AAK1和GAK干預重癥登革熱的實驗研究， 2018/08-2020/08，結題

近期代表性論文

1.  Xiao F^#, Tang M^#, Zheng X^#, Liu Y*, Li X*, Shan H*. Evidence for gastrointestinal infection of SARS-CoV-2. Gastroenterology. 2020; 158(6): 1831-1833.e3

2. Xiao F, Tang M, Shan H. Reply to Letter to the Editor: Presence of SARS-Coronavirus-2 in the ileal mucosa: another evidence for infection of GI tract by this virus (GASTRO-D-20-01382). Gastroenterology. 2020; S0016-5085(20)35167-2

3. Xiao F^#, Fofana I^#, Thumann C, Alles R, Mailly L, Robinet E, Meyer N, Schaeffer M, Habersetzer F, Doffo?l M, Leyssen P, Neyts J, Zeisel MB, Baumert TF*. Synergy of entry inhibitors with direct-acting antivirals uncovers novel combinations for prevention and treatment of hepatitis C. Gut. 2015; 64(3): 483-494

4. Xiao F, McKeating JA, Baumert TF*. A bile acid transporter as a candidate receptor for hepatitis B and D virus entry. Journal of Hepatology. 2013; 58(6): 1246-1248

5. Xiao F, Wang S, Barouch-Bentov R, Neveu G, Pu S, Beer M, Schor S, Kumar S, Nicolaescu V, Lindenbach BD, Randall G, Einav S.Interactions between the Hepatitis C Virus Nonstructural 2 Protein and Host Adaptor Proteins 1 and 4 Orchestrate Virus Release. mBio. 2018; 9(2): e02233-17

6. Xiao F^#, Fofana I^#, Heydmann L, Barth H, Soulier E, Habersetzer F, Doffo?l M, Bukh J, Patel AH, Zeisel MB, Baumert TF*. Hepatitis C virus cell-cell transmission and resistance to direct-acting antiviral agents. PLoS Pathogens. 2014; 10: e1004128

7. Xiao F^#, Sun J^#, Xu Y^#, Li F#, Huang X^#, Li H, Zhao J, Huang J, Zhao J*. Infectious SARS-CoV-2 in Feces of Patient with Severe COVID-19. Emerging Infectious Diseases. 2020; 26(8):1920-1922.

8. Zhu C^#, Xiao F^#, Hong J, Wang K, Fusco DN, Zhao L, Jeong SW, Brisac C, Chusri E, Schaefer EA, Zhao H, Peng LF, Lin W*, Chung RT*. EFTUD2 is a novel innate immune regulator restricting hepatitis C virus infection through the RIG-I/MDA5 pathway. Journal of Virology. 2015; 89(13): 6608-6618

9. Pu S^#, Xiao F^#, Schor S, Bekerman E, Zanini F, Barouch-Bentov R, Nagamine CM, Einav S*. Feasibility and biological rationale of repurposing sunitinib and erlotinib for dengue treatment. Antiviral Research. 2018; 155: 67-75

10. Huang M^#, Li M^#, Xiao F^#, Pang P^#, Liang J^#, Tang T^#, Liu S, Chen B, Shu J, You Y, Li Y, Tang M, Zhou J, Jiang G, Xiang J, Hong W, He S, Wang Z, Feng J, Lin C, Ye Y, Wu Z, Li Y, Zhong B, Sun R, Hong Z, Liu J, Chen H, Wang X, Li Z, Pei D*, Tian L*, Xia J*, Jiang S*, Zhong N*, Shan H*, Preliminary evidence from a multicenter prospective observational study of the safety and efficacy of chloroquine for the treatment of COVID-19, National Science Review. 2020; 7(9): 1428–1436

11. Zhong H^#, Wang Y^#, Shi Z^#, Zhang L^#, Ren H^#, He W^#, Zhang Z^#, Zhu A^#, Zhao J^#, Xiao F^#, Yang F, Liang T, Ye F, Zhong B, Ruan S, Gan M, Zhu J, Li F, Li F, Wang D, Li J, Ren P, Zhu S, Yang H, Wang J, Kristiansen K, Tun HM, Chen W, Zhong N, Xu X*, Li YM*, Li J*, Zhao J*. Characterization of respiratory microbial dysbiosis in hospitalized COVID-19 patients. Cell Discovery. 2021;7(1):23

12. Kang S^#, Yang M^#, He S^#, Wang X^#, Chen X, Chen Y, Hong Z, Liu J, Jiang G, Chen Q, Zhou Z, Zhou Z, Huang Z, Huang X, He H, Zheng W, Liao HX*, Xiao F*, Shan H*, Chen S*. A SARS-CoV-2 antibody curbs viral nucleocapsid protein induced complement hyperactivation. Nature Communications. 2021; 12(1): 2697

13. Chen Y^#, He R^#, Han Z, Wu Y, Wang Q, Zhu X, Huang Z, Ye J, Tang Y, Huang H, Chen J, Shan H*, Xiao F*. Cooperation of ATF4 and CTCF promotes adipogenesis transcriptional regulation. Cell Biology and Toxicology. 2021; Online ahead of print

14. Xu Z^#, Tang M^#, Chen P^#, Cai H^# and Xiao F*.  SARS-CoV-2 gastrointestinal infection prolongs the time to recover from COVID-19. Frontiers in Medicine. 2021; 8:683551

15. Li Y, Zhu C, Wang F, Zhu T, Li J*, Liu S, Xiao F*. Expression of interferon effector gene SART1 correlates with interferon treatment response against hepatitis B infection. Mediators of Inflammation. 2016; 2016: 3894816

16. Fu L^#, Fang Y^#, Luo D^#, Wang B^#, Xiao X, Hu Y, Niu Y, Zheng W, Xu H, Yang X, Chan PSF, Xu Z, Chen P, He J, Zhu H, Tang H, Huang D, Hong Z, Ma X, Hao Y, Cai L, Yang J, Ye S, Yuan J, Chen Y, Xiao F*, Wang Z*, Zou H*. (2021). Pre-hospital, in-hospital and post-hospital factors associated with sleep quality among COVID-19 survivors 6 months after hospital discharge: Cross-sectional survey in five cities in China. BJPsych Open. 2021; 7(6): e191

17. Mailly L, Xiao F, Lupberger J, Wilson GK, Aubert P, Duong FHT, Calabrese D, Leboeuf C, Fofana I, Thumann C, Bandiera S, Lütgehetmann M, Volz T, Davis C, Harris HJ, Mee C, Girardi E, Chane-Woon-Ming B, Ericsson M, Fletcher N, Bartenschlager R, Pessaux P, Vercauteren K, Meuleman P, Villa P, Kaderali L, Pfeffer S, Heim MH, Neunlist M, Zeisel MB, Dandri M, McKeating JA, Robinet E, Baumert TF. Clearance of persistent hepatitis C virus infection in humanized mice using a claudin-1-targeting monoclonal antibody. Nature Biotechnology. 2015, 33(5): 549-554

18. Lupberger J^#, Zeisel MB^#, Xiao F, Thumann C, Fofana I, Zona L, Davis C, Mee CJ, Turek M, Gorke S, Royer C, Fischer B, Zahid MN, Lavillette D, Fresquet J, Cosset FL, Rothenberg SM, Pietschmann T, Patel AH, Pessaux P, Doffoel M, Raffelsberger W, Poch O, McKeating JA, Brino L, Baumert TF*. EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nature Medicine. 2011;17(5): 589-595

入選國家重大人才工程

獲批教育部“雙帶頭人”工作室建設

湖北省“百人計劃”

廣東省杰出青年醫學人才

廣東省抗擊新冠肺炎疫情先進個人

廣東好醫生

中山大學“百人計劃”

珠海市“英才計劃”
珠海好人（敬業奉獻好人）